Harbin Jixianglong Biotech Co., Ltd.
Has Harbin Jixianglong Biotech Co., Ltd. received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Harbin Jixianglong Biotech Co., Ltd. a warning letter naming semaglutide and tirzepatide, dated May 1, 2026, with the FDA subject line “CGMP/API/Adulterated and Misbranded Drugs.” openFDA also lists 2 drug recall reports for the firm naming semaglutide.
FDA records in this index name Harbin Jixianglong Biotech Co., Ltd. from Feb 13, 2026 to May 1, 2026.
- Type named in FDA records
- API manufacturer
- FDA warning letters
- 1
- Drug recall reports
- 2
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- May 1, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| May 1, 2026 | CGMP/API/Adulterated and Misbranded Drugs | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- May 1, 2026: … to provide drug listing information for your relabeled semaglutide as required under section 510(j) of the FD&C Act, … 360(j), and 21 CFR Part 207. Furthermore, your relabeled semaglutide was manufactured in an establishment not duly … These violations are described in more detail below. Your semaglutide API is also misbranded under sections 502(a) and … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Feb 13, 2026 | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; ... | CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be... | Class II | Ongoing | D-0380-2026 |
| Feb 13, 2026 | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d... | CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be... | Class II | Ongoing | D-0379-2026 |
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 2 products naming retatrutide and tirzepatide under the labeler name “Harbin Jixianglong Biotech Co., Ltd.”, matched to this company page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (2).
| 84385-103 | Not given | Retatrutide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | Jan 9, 2025 | None given | Dec 31, 2026 | Unfinished drugs |
| 84385-104 | Not given | Tirzepatide | POWDER | Not given | 100 g/100g | BULK INGREDIENT | May 9, 2025 | None given | Dec 31, 2027 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, May 1, 2026
- openFDA drug recall enforcement reports
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.